“We continue to make strong progress advancing lorundrostat toward potential approval, moving closer towards our goal of delivering what we believe has the potential to be a best-in-class aldosterone synthase inhibitor for patients with uncontrolled or resistant hypertension,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics (MLYS). “The FDA’s acceptance of our NDA in the first quarter marks a significant milestone for Mineralys. We continue to advance pre-commercial activities to support a successful launch of lorundrostat while maintaining strategic flexibility.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics initiated with a Buy at TD Cowen
- Immunic appoints Mineralys Therapeutics CEO Jon Congleton to board
- Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer
- Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
- Mineralys Therapeutics Charts Path After NDA Acceptance